Serum S100 Levels and Survival in Melanoma
Author Information
Author(s): J Buerl, M Probst, A Franzke, S Duensing, J Haindl, M Volkenandt, F Wittke, R Hoffmann, A Ganser, J Atzpodien
Primary Institution: Medizinische Hochschule Hannover
Hypothesis
Elevated serum levels of S100 are correlated with poor outcomes in patients with metastatic malignant melanoma.
Conclusion
Elevated serum levels of S100 are associated with poorer survival in patients with metastatic malignant melanoma, but do not provide additional prognostic information beyond established clinical parameters.
Supporting Evidence
- Elevated serum levels of S100 were detected in 22 patients and were associated with a median survival of 6 months.
- Patients with serum S100 below 3 µg/l achieved a median survival of 13 months.
- LDH and liver metastases were found to be significant independent prognostic factors.
Takeaway
This study found that higher levels of a protein called S100 in the blood can mean that patients with a type of skin cancer called melanoma might not live as long.
Methodology
The study used univariate and multivariate Cox proportional-hazards models to analyze serum S100 levels and clinical factors in relation to overall survival.
Limitations
S100 lost its statistical significance when combined with other prognostic markers, indicating it may not be independently useful.
Participant Demographics
Patients with histologically confirmed metastatic malignant melanoma, with a performance status of 70% or higher.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI 0.43-0.70 for serum LDH; 95% CI 0.59-0.98 for liver metastases
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website